Skip to main content

Table 1 Summary of parameters, range and parameter distribution used in sensitivity analysis

From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

Parameters

Reference case

Minimal value

Maximal value

Distribution

References

Genetic alterations

 Prevalence EGFR

0.28

0.22

0.34

Beta

[28, 29]

 Prevalence Alk

0.05

0.02

0.07

Beta

[7, 28]

 Prevalence Ros1

0.02

0.01

0.03

Beta

[8, 30]

Test accuracy

 Sensitivity EGFR

0.98

0.95

0.99

Beta

[12, 31,32,33]

 Specificity EGFR

0.89

0.69

1.00

Beta

[12, 31,32,33]

 Sensitivity Alk

1.00

0.75

1.00

Beta

[34]

 Specificity Alk

1.00

1.00

1.00

Beta

[34]

 Sensitivity Ros1

1.00

0.75

1.00

Beta

Assumption, as reference test

 Specificity Ros1

1.00

1.00

1.00

Beta

Assumption, as reference test

 Sensitivity NGS

0.99

0.96

1.00

Beta

[35, 36]

 Specificity NGS

1.00

0.82

1.00

Beta

[35, 36]

Test performance

 pUnknow EGFR

0.13

0.06

0.34

Beta

[12, 31,32,33]

 pUnknow FISH (ALK e ROS)

0.10

0.02

0.38

Beta

[37, 38]

 pUnknow NGS

0.04

0.00

0.09

Beta

[39,40,41]

Test costs

 cEGFR

428.14

363.57

477.39

Gama

AMB, CBHPM - 2016; ANS,D-TISS; search from current Brazilian market price

 cFISH Alk

573.70

423.11

753.77

Gama

 cFISH Ros1

564.99

423.11

753.77

Gama

 cNGS

1874.37

1502.51

2110.55

Gama

Drug price

 Cisplatin 50 mg

113.57

63.11

141.95

Gama

Anvisa, Câmara de Regulação do Mercado de Medicamentos - CMED

 Crizotinib 250 mg

15,084.79

11,245.02

19,298.94

Gama

 Docetaxel 80 mg

1271.57

1463.21

1589.47

Gama

 Gefitinib 250 mg

2256.31

1631.86

2820.38

Gama

 Gencitabin 1000 mg

1881.43

799.77

2351.78

Gama

 Pemetrexed 500 mg

3418.88

2484.86

4273.60

Gama

Utilities

 1st line with Gefitinib (M1)

0.65

0.60

0.71

Beta

[37, 38]

 1st line with Crizotinib (M2)

0.66

0.60

0.71

Beta

[37, 38]

 Pemetrexed + cisplatin (M3, 1st Progression in M1 & M2)

0.62

0.56

0.67

Beta

[37, 38]

 2nd or 3rd line with standard chemotherapy (2nd Progression in M1, M2, M3 and 1st Progression in M3)

0.57

0.51

0.64

Beta

[37, 38]

Others

Discount rate

0.05

0.00

0.10

Beta

[27]